Tradestie Institutional Equity Comparison Engine

AAPG vs CDT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AAPG Overall Edge

AAPG Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ascentage Pharma Group International American Depository Shares (AAPG) driven by superior Valuation, Momentum & Technical, Options & Structure while CDT counters with relative strength in Growth & Margin. Fundamentally, AAPG trades at 8.4x Forward P/E with -219.5% operating margin (+29.3% YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, AAPG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner AAPG
AAPG 8.4x vs CDT N/M Fwd P/E
Growth & Margin Winner CDT
Op Margin -219.5% vs 0.0% ยท YoY +29.3% vs +0.0%
Momentum & Technical Winner AAPG
1Y -64.0% vs -86.8% ยท 52W Pos 0% vs 2%
Options & Structure Winner AAPG
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
AAPG NASDAQ
Ascentage Pharma Group International American Depository Shares
Pharmaceutical Preparations
$11.97
-3.78% 1D
Market Cap $1.2B
1M Return -19.77%
1Y Return -64.0%
Forward P/E 8.4x
Unified AI Score
37.1 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
1M Return +76.79%
1Y Return -86.78%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AAPG -64.0% CDT -86.78% Spread: +23.95 pp (AAPG Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AAPG TTM Op. Margin: -219.5% CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAPG vs CDT. Trailing 12-month operating profitability (AAPG -219.5% vs CDT 0.0%) and valuation multiples (AAPG 8.4x vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AAPG (6) vs CDT (4)
Institutional Metric AAPG CDT Criterion Row Winner
Market Capitalization Scale $1.2B $507,528 Larger Scale AAPG
Trailing P/E Ratio Valuation 8.4x N/M Lower Multiple AAPG
Forward P/E Ratio Valuation 8.4x N/M Lower Multiple AAPG
Revenue Growth (YoY) Growth +29.3% +0.0% Higher Growth AAPG
Operating Margin (TTM) Profitability -219.5% 0.0% Higher Margin CDT
Net Profit Margin Profitability -228.5% 0.0% Higher Margin CDT
Return on Equity (ROE) Capital Efficiency -236.6% -69.7% Higher ROE CDT
52-Week Range Position Momentum 0% ($12โ€“$34) 2% ($0โ€“$11) Stronger Trend CDT
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 64% Vol -17.75ฮฒ ยท 10175% Vol Lower Realized Risk AAPG
Unified Institutional Score Composite Signal 37.1 / 100 (SELL) 31.6 / 100 (SELL) Higher Composite AAPG

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AAPG vs CDT Buy Guide
AAPG UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AAPG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AAPG nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.